| Comparative assessment of the absorption of a generic formulation of 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet against the innovator 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet conducted under fasting conditions in healthy male and female volunteers | A single dose, randomized, blinded, pharmacokinetic study of a generic formulation of 2.5 mg 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet against the innovator 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet conducted under fasting conditions in healthy volunteers. | ACTRN12622001178730 |
